Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer

Annals of Surgical Oncology
Lucy M De La Cruz, Brian J Czerniecki

Abstract

Although immunotherapy is making rapid inroads as a major treatment method for melanoma, lung, bladder, and hereditary colon cancer, breast cancer (BC) remains one of the tumors yet to experience the cellular immunology explosion despite the fact that heavy lymphocyte responses in breast tumors improve response to therapy and can predict for long-term survival. Immunotherapies in the form of monoclonal antibodies such as trastuzumab and pertuzumab have had an impact on HER2-positive breast cancer (HER2+BC) treatment through antibody-dependent cellular cytotoxicity. Current evidence suggests that checkpoint inhibitors and other cellular therapies are at the doorstep of improving outcomes in triple-negative BC (TNBC) and HER2+BC, especially when combined with standard therapies. Although this approach has benefitted small numbers of patients to date, numerous clinical trials are underway to define the relative role immunotherapy may play in the treatment of BC.

References

Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Jan 24, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Caroline BouzinOlivier Feron
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth A ManningLeisha A Emens
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sylvain LadoireFrançois Ghiringhelli
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniele GeneraliStephen B Fox
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Mar 17, 2012·Breast Cancer Research : BCR·Shuzhen LiuTorsten O Nielsen
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Oct 5, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chunling MaGuangyong Peng
Jul 31, 2013·Immunity·Greg T Motz, George Coukos
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Feb 12, 2014·Cancer Immunology, Immunotherapy : CII·Shenyou SunKunwei Shen
Mar 8, 2014·Oncoimmunology·Eric D Mortenson, Yang-Xin Fu
Apr 30, 2014·Cancer Immunology Research·Hye-Jung Kim, Harvey Cantor
Jun 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Nov 30, 2014·Breast Cancer Research : BCR·Elena García-MartínezFrancisco Ayala de la Peña
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
Feb 12, 2015·Oncotarget·Renaud SabatierFrançois Bertucci
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
May 21, 2015·American Society of Clinical Oncology Educational Book·Mary L Disis, Sasha E Stanton
May 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciA Goubar
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre

❮ Previous
Next ❯

Citations

Oct 31, 2019·Cancers·Ayelet Alfasi, Irit Ben-Aharon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Reviews on Recent Clinical Trials
Masataka Sawaki
Recenti progressi in medicina
Francesco Spagnolo
The Lancet Oncology
Filippo Montemurro, Massimo Aglietta
Deutsche medizinische Wochenschrift
Tanja Fehm, Volkmar Müller
© 2022 Meta ULC. All rights reserved